YpsomedPrefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Ypsomed (YPSN.SW) reported revenue of $416.00M in Q1 2026.
YpsomedSwiss drug-delivery device maker. Primary autoinjector pen supplier to Novo Nordisk for Wegovy and Ozempic. Pen business growing on GLP-1 pen attach.
Ypsomed (YPSN.SW) is a Medical Devices company. Swiss drug-delivery device maker. Primary autoinjector pen supplier to Novo Nordisk for Wegovy and Ozempic. Pen business growing on GLP-1 pen attach. It was founded in 1984, is headquartered in Burgdorf, Switzerland and employs about 2,400 people.
Track Ypsomed's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated September 28, 2026.
Sterling groups Ypsomed in the GLP-1 industry, alongside Insulet (PODD), DexCom (DXCM) and West Pharmaceutical Services (WST).
If you are researching Ypsomed, also look at Insulet (PODD), DexCom (DXCM) and West Pharmaceutical Services (WST). You can compare all of them side by side or browse the full GLP-1 industry on Sterling.
Q2 2016-Q1 2026
Q2 2016-Q1 2026